Skip to main content

Shanmugam Muthusamy's Form 4 filing

Ani Pharmaceuticals Inc (ANIP) · filed Oct 19, 2023

Accession no.
0001870913-23-000011
Filed
Oct 19, 2023
Trade date
Oct 17-19, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions. Open-market sales total $1.44M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Shanmugam MuthusamyCIK 0001870913Director, Officer (HEAD OF R&D, COO-NOVITIUM OPS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 17, 2023Common StockSSaleDisposed−8,758$58.53F2−$512,605.741,048,862Indirect
Oct 18, 2023Common StockSSaleDisposed−6,242$57.78F4−$360,662.761,042,620Indirect
Oct 19, 2023Common StockSSaleDisposed−10,000$57.06F5−$570,6001,032,620Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $58.03 to $59.47, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $57.15 to $58.41, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $56.50 to $57.69, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)